Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,600 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 11,600 shares of the firm’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $18.03, for a total transaction of $209,148.00. Following the sale, the director owned 8,390 shares in the company, valued at approximately $151,271.70. This represents a 58.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Up 7.8%

DYN stock opened at $18.84 on Thursday. The firm has a market cap of $3.11 billion, a PE ratio of -5.32 and a beta of 1.08. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. The firm’s fifty day moving average is $18.01 and its 200 day moving average is $18.58. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). On average, research analysts forecast that Dyne Therapeutics, Inc. will post -2.94 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DYN. T. Rowe Price Investment Management Inc. lifted its stake in shares of Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares in the last quarter. Orbis Allan Gray Ltd purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth about $93,926,000. Adage Capital Partners GP L.L.C. purchased a new position in Dyne Therapeutics during the second quarter worth about $30,378,000. Perceptive Advisors LLC raised its stake in Dyne Therapeutics by 543.7% during the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after purchasing an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP raised its stake in Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on DYN shares. JPMorgan Chase & Co. dropped their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. HC Wainwright dropped their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 2nd. Finally, Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.